The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
ABTB1 (ankyrin repeat and BTB/POZ domain-containing protein 1; synonym BPOZ) is a human BTB/POZ-domain protein with ankyrin repeats, best interpreted as a protein–protein interaction scaffold and putative CUL3-type E3 ubiquitin ligase substrate adaptor based on the established role of BTB/POZ proteins in CUL3 complexes. Direct ABTB1 biochemical substrate(s) and definitive subcellular localization are not well established in the retrieved literature, but ABTB1 is repeatedly linked to PTEN growth-suppressive signaling and shows context-dependent associations with proliferation and cancer outcomes. Strong experimental evidence supports post-transcriptional regulation of ABTB1 by miR-125b. Recent clinical/transcriptomic data (2023) support ABTB1 expression as a prognostic correlate in prostate cancer.
The literature and database evidence retrieved aligns with the human gene ABTB1 (Ensembl ENSG00000114626), approved name “ankyrin repeat and BTB domain containing 1,” consistent with the UniProt entry Q969K4 and the stated synonym BPOZ. (OpenTargets Search: -ABTB1)
Multiple sources describe ABTB1 as a mediator of PTEN-dependent growth suppressive signaling and as anti-proliferative/tumor suppressive in some experimental contexts. In a 2023 prostate cancer transcriptomic analysis, the authors summarize prior literature that ABTB1 overexpression inhibits cell growth and G1/S progression in vitro, while noting uncertainty regarding which ABTB1 isoform(s) mediate growth inhibition. (natkin2023adaptiveandnonadaptive pages 14-15)
A 2023 study of prostate cancer cell models under androgen deprivation and castration-tolerant adaptation reports ABTB1 as one of the androgen receptor (AR)-associated genes whose expression changes with testosterone depletion and is maintained in adapted cells. The authors interpret their results to suggest that low ABTB1 expression correlates with better progression-free survival and propose ABTB1 inhibition as a hypothesis for suppressing prostate cancer cell proliferation. (natkin2023adaptiveandnonadaptive pages 14-15)
Key quantitative statistic (TCGA PRAD cohort multivariable Cox model):
* For ABTB1, hazard ratio (HR) = 0.46 for low vs high expression, 95% CI 0.28–0.74, p = 0.0013 for biochemical relapse or clinical tumor progression. (natkin2023adaptiveandnonadaptive media 40d79004)
Interpretation: HR < 1 indicates lower risk for the low-expression group (per the table definition), implying that higher ABTB1 expression is associated with worse progression-free survival in this dataset/modeling frame. (natkin2023adaptiveandnonadaptive media 40d79004)
Open Targets aggregates ABTB1 disease-association evidence including GWAS credible sets and a CRISPRi screen in glutamatergic neurons (peroxidized lipid phenotype). Reported target–disease association scores include refractive error (0.2878), asthma (0.2681), and neurodegenerative disease (0.1988), among others. While these scores are not effect sizes, they highlight domains where ABTB1 may be implicated by genetics and functional screens. (OpenTargets Search: -ABTB1)
A 2024 BTB-domain-focused structural/biophysical thesis emphasizes that BTB proteins can serve as E3 ligase substrate adaptors and that atypical/tandem BTB architectures exhibit heterogeneity in oligomerization and CUL3 binding affinities across the class; this supports the plausibility that ABTB1’s BTB/POZ architecture could engage CUL3-like systems, although ABTB1-specific binding constants were not extracted from the available pages. (walma2024structureandfunction pages 1-8)
In myeloid cell-line models, ABTB1 is experimentally supported as a direct miR-125b target:
* ABTB1 mRNA down-regulated 3.9-fold in miR-125b overexpressing cells vs control. (bousquet2012microrna125btransformsmyeloid pages 6-7)
* ~60% decrease in ABTB1 protein with miR-125b overexpression and ~40% increase with miR-125b inhibitor. (bousquet2012microrna125btransformsmyeloid pages 6-7)
* Luciferase 3'UTR reporter assay validated direct targeting (loss of repression when target site mutated). (bousquet2012microrna125btransformsmyeloid pages 6-7)
Visual evidence supporting these claims (Figure 4 panels with qRT-PCR, Western blot, and luciferase assay) was retrieved. (bousquet2012microrna125btransformsmyeloid media a60edfbb, bousquet2012microrna125btransformsmyeloid media f18b171a)
As above, ABTB1 low vs high expression HR 0.46 (95% CI 0.28–0.74; p=0.0013) for progression-free survival in a multivariable Cox regression on TCGA prostate adenocarcinoma data. (natkin2023adaptiveandnonadaptive media 40d79004)
Open Targets provides association and evidence scores (platform-derived metrics):
* Target–disease association scores: refractive error 0.2878; asthma 0.2681; neurodegenerative disease 0.1988; abnormality of refraction 0.1418; sialolithiasis 0.0452. (OpenTargets Search: -ABTB1)
* Evidence item scores include 0.77882 and 0.72245 (GWAS credible sets) and 0.52786 (glutamatergic neuron CRISPRi screen). (OpenTargets Search: -ABTB1)
| Topic | Key findings | Evidence type | Source (first author year) | Publication date | URL | Notes/limitations |
|---|---|---|---|---|---|---|
| identity/domains | ABTB1 is the human gene/protein targeted here (approved symbol ABTB1; synonym BPOZ), encoding an ankyrin repeat and BTB domain-containing protein; Open Targets lists ENSG00000114626 with approved name “ankyrin repeat and BTB domain containing 1.” (OpenTargets Search: -ABTB1) | Database annotation / target curation | Open Targets | 2025 platform paper; underlying evidence earlier | https://platform.opentargets.org/target/ENSG00000114626 | Database-level identity support; does not by itself prove mechanism. |
| identity/domains | BTB/POZ-domain proteins are a large eukaryotic family proposed to act as substrate-specific adaptors for CUL3 ubiquitin ligases; this family-level model is consistent with ABTB1’s BTB/POZ architecture. (geyer2003btbpozdomainproteins pages 7-8, geyer2003btbpozdomainproteins pages 1-2, geyer2003btbpozdomainproteins pages 4-6) | Biochemical complex biology / family inference | Geyer 2003 | Sep 2003 | https://doi.org/10.1016/S1097-2765(03)00341-1 | Evidence is family-level and yeast-centered; not direct human ABTB1 biochemistry. |
| molecular function | ABTB1 is described as a tumor suppressor and mediator of PTEN growth-suppressive signaling; prior work cited in later papers reports that ABTB1 overexpression decreases proliferation and inhibits G1/S progression in vitro. (bousquet2012microrna125btransformsmyeloid pages 6-7, natkin2023adaptiveandnonadaptive pages 14-15) | Functional cell biology / literature synthesis | Bousquet 2012; Nätkin 2023 | Nov 2012; Feb 2023 | https://doi.org/10.3324/haematol.2011.061515 ; https://doi.org/10.1371/journal.pone.0281645 | Primary direct mechanistic substrate of ABTB1 remains unclear in available context. |
| regulation | In myeloid cells, ABTB1 is a direct miR-125b target: ABTB1 mRNA was down-regulated 3.9-fold, protein decreased by ~60% with miR-125b overexpression, and increased ~40% with miR-125b inhibitor; luciferase assays validated direct 3'UTR targeting. (bousquet2012microrna125btransformsmyeloid pages 6-7, bousquet2012microrna125btransformsmyeloid media a60edfbb, bousquet2012microrna125btransformsmyeloid media f18b171a) | Expression analysis / reporter assay / immunoblot | Bousquet 2012 | Nov 2012 | https://doi.org/10.3324/haematol.2011.061515 | Strong evidence for post-transcriptional regulation; effect shown in hematopoietic model rather than all tissues. |
| pathways | ABTB1 is repeatedly linked to PTEN growth-suppressive signaling; in prostate cancer transcriptomic analysis it remained androgen receptor (AR)-associated under androgen-deprivation adaptation. (natkin2023adaptiveandnonadaptive pages 14-15) | Expression/pathway analysis | Nätkin 2023 | Feb 2023 | https://doi.org/10.1371/journal.pone.0281645 | Pathway placement is partly based on prior literature cited by authors rather than direct pathway biochemistry in this paper. |
| localization | Direct ABTB1 localization evidence was limited in the retrieved human-focused context; no robust subcellular localization for human ABTB1 was established from the cited excerpts. (natkin2023adaptiveandnonadaptive pages 14-15) | Evidence gap | — | — | — | Important limitation: localization should not be overstated from current context. |
| disease/clinical associations | In prostate cancer, ABTB1 low vs high expression was associated with better progression-free survival in TCGA-based Cox analysis; authors therefore suggested ABTB1 inhibition might suppress prostate cancer cell proliferation. (natkin2023adaptiveandnonadaptive pages 14-15, natkin2023adaptiveandnonadaptive media 40d79004) | Expression/survival analysis | Nätkin 2023 | Feb 2023 | https://doi.org/10.1371/journal.pone.0281645 | Association is correlative and context-specific; contrasts with anti-proliferative narrative in other systems, implying context dependence or isoform complexity. |
| disease/clinical associations | Open Targets reports ABTB1 associations with refractive error, asthma, neurodegenerative disease, abnormality of refraction, and sialolithiasis, supported by GWAS credible sets and a glutamatergic-neuron CRISPRi screen. (OpenTargets Search: -ABTB1) | Genetic association / functional genomics | Open Targets | 2025 platform paper; evidence PMIDs earlier | https://platform.opentargets.org/target/ENSG00000114626 | Platform scores support prioritization, but causal mechanism and effect sizes are not provided in the retrieved context. |
| quantitative stats | Prostate cancer progression-free survival: ABTB1 low vs high expression HR 0.46, 95% CI 0.28–0.74, p=0.0013. (natkin2023adaptiveandnonadaptive media 40d79004) | Multivariable survival statistic | Nätkin 2023 | Feb 2023 | https://doi.org/10.1371/journal.pone.0281645 | Statistic comes from table image extraction; clinical endpoint defined as biochemical relapse or clinical tumor progression. |
| quantitative stats | Open Targets association scores for ABTB1 include refractive error 0.2878, asthma 0.2681, neurodegenerative disease 0.1988, abnormality of refraction 0.1418, and sialolithiasis 0.0452; individual evidence scores included 0.77882, 0.72245, and 0.52786 for specific evidence items. (OpenTargets Search: -ABTB1) | Prioritization scores / platform metrics | Open Targets | 2025 platform paper | https://platform.opentargets.org/target/ENSG00000114626 | Scores are platform-derived prioritization metrics, not direct effect sizes like odds ratios or hazard ratios. |
Table: This table summarizes the main experimentally or computationally supported functional annotation evidence for human ABTB1 (UniProt Q969K4). It highlights what is known with direct support, what remains inferential, and where the strongest quantitative evidence currently lies.
Key sources include:
* Geyer et al., Molecular Cell (Sep 2003). https://doi.org/10.1016/S1097-2765(03)00341-1 (geyer2003btbpozdomainproteins pages 1-2)
* Bousquet et al., Haematologica (Nov 2012). https://doi.org/10.3324/haematol.2011.061515 (bousquet2012microrna125btransformsmyeloid pages 6-7)
* Nätkin et al., PLOS ONE (Feb 21, 2023). https://doi.org/10.1371/journal.pone.0281645 (natkin2023adaptiveandnonadaptive pages 14-15, natkin2023adaptiveandnonadaptive media 40d79004)
* Open Targets Platform (evidence aggregated; platform paper 2025). https://platform.opentargets.org/target/ENSG00000114626 (OpenTargets Search: -ABTB1)
References
(OpenTargets Search: -ABTB1): Open Targets Query (-ABTB1, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(geyer2003btbpozdomainproteins pages 1-2): Rory Geyer, Susan Wee, Scott Anderson, John Yates, and Dieter A. Wolf. Btb/poz domain proteins are putative substrate adaptors for cullin 3 ubiquitin ligases. Molecular cell, 12 3:783-90, Sep 2003. URL: https://doi.org/10.1016/s1097-2765(03)00341-1, doi:10.1016/s1097-2765(03)00341-1. This article has 428 citations and is from a highest quality peer-reviewed journal.
(geyer2003btbpozdomainproteins pages 4-6): Rory Geyer, Susan Wee, Scott Anderson, John Yates, and Dieter A. Wolf. Btb/poz domain proteins are putative substrate adaptors for cullin 3 ubiquitin ligases. Molecular cell, 12 3:783-90, Sep 2003. URL: https://doi.org/10.1016/s1097-2765(03)00341-1, doi:10.1016/s1097-2765(03)00341-1. This article has 428 citations and is from a highest quality peer-reviewed journal.
(natkin2023adaptiveandnonadaptive pages 14-15): Reetta Nätkin, Pasi Pennanen, Heimo Syvälä, Merja Bläuer, Juha Kesseli, Teuvo L. J. Tammela, Matti Nykter, and Teemu J. Murtola. Adaptive and non-adaptive gene expression responses in prostate cancer during androgen deprivation. PLOS ONE, 18:e0281645, Feb 2023. URL: https://doi.org/10.1371/journal.pone.0281645, doi:10.1371/journal.pone.0281645. This article has 3 citations and is from a peer-reviewed journal.
(natkin2023adaptiveandnonadaptive media 40d79004): Reetta Nätkin, Pasi Pennanen, Heimo Syvälä, Merja Bläuer, Juha Kesseli, Teuvo L. J. Tammela, Matti Nykter, and Teemu J. Murtola. Adaptive and non-adaptive gene expression responses in prostate cancer during androgen deprivation. PLOS ONE, 18:e0281645, Feb 2023. URL: https://doi.org/10.1371/journal.pone.0281645, doi:10.1371/journal.pone.0281645. This article has 3 citations and is from a peer-reviewed journal.
(walma2024structureandfunction pages 1-8): DA Cruz Walma. Structure and function of atypical btb domains in health and disease. Unknown journal, 2024.
(bousquet2012microrna125btransformsmyeloid pages 6-7): Marina Bousquet, D. Nguyen, Cynthia Chen, L. Shields, and H. Lodish. Microrna-125b transforms myeloid cell lines by repressing multiple mrna. Haematologica, 97:1713-1721, Nov 2012. URL: https://doi.org/10.3324/haematol.2011.061515, doi:10.3324/haematol.2011.061515. This article has 86 citations.
(bousquet2012microrna125btransformsmyeloid media a60edfbb): Marina Bousquet, D. Nguyen, Cynthia Chen, L. Shields, and H. Lodish. Microrna-125b transforms myeloid cell lines by repressing multiple mrna. Haematologica, 97:1713-1721, Nov 2012. URL: https://doi.org/10.3324/haematol.2011.061515, doi:10.3324/haematol.2011.061515. This article has 86 citations.
(bousquet2012microrna125btransformsmyeloid media f18b171a): Marina Bousquet, D. Nguyen, Cynthia Chen, L. Shields, and H. Lodish. Microrna-125b transforms myeloid cell lines by repressing multiple mrna. Haematologica, 97:1713-1721, Nov 2012. URL: https://doi.org/10.3324/haematol.2011.061515, doi:10.3324/haematol.2011.061515. This article has 86 citations.
(geyer2003btbpozdomainproteins pages 6-7): Rory Geyer, Susan Wee, Scott Anderson, John Yates, and Dieter A. Wolf. Btb/poz domain proteins are putative substrate adaptors for cullin 3 ubiquitin ligases. Molecular cell, 12 3:783-90, Sep 2003. URL: https://doi.org/10.1016/s1097-2765(03)00341-1, doi:10.1016/s1097-2765(03)00341-1. This article has 428 citations and is from a highest quality peer-reviewed journal.
(geyer2003btbpozdomainproteins pages 7-8): Rory Geyer, Susan Wee, Scott Anderson, John Yates, and Dieter A. Wolf. Btb/poz domain proteins are putative substrate adaptors for cullin 3 ubiquitin ligases. Molecular cell, 12 3:783-90, Sep 2003. URL: https://doi.org/10.1016/s1097-2765(03)00341-1, doi:10.1016/s1097-2765(03)00341-1. This article has 428 citations and is from a highest quality peer-reviewed journal.